Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: Provided are pharmaceutical compositions which comprise a mixture of a lipophilic active pharmaceutical ingredient, at least one long chain fatty acid or at least one fatty acid glyceride, a surfactant, and optionally an antioxidant. Also described are methods for preparing and using such pharmaceutical compositions. The active pharmaceutical ingredient in such a combination has improved bioavailability compared to the active pharmaceutical ingredient alone.

Abstract: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17?-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3?-acetoxy-17-(3-pyridyl) androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17?-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

Abstract: In some aspects, the disclosure relates to methods for screening clinical samples for the presence of L-form bacteria associated with endometriosis and/or ovarian fibroid tumors. The disclosure is based, in part, on screening methods used to diagnose a subject as likely having or likely not having endometriosis and/or an ovarian fibroid tumor. In some embodiments, the disclosure relates to methods of treating endometriosis by administering an antibiotic to a subject that has been determined to be infected by one or more strains of L-form bacteria.

Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Abstract: Solid compositions having about 150 mg to about 245 mg Fosaprepitant that are stable after storage at about 25° C. for 6 months and processes for preparing solid Fosaprepitant compositions that are stable after long term storage at room temperature. The processes include freezing a Fosaprepitant solution in the primary packaging container at a first freezing temperature; applying vacuum at second temperature that is higher than the freezing temperature; fully stoppering the primary packaging container; and sealing the stoppered primary packaging container.

Abstract: Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.

Abstract: The present invention provides a food that is effective for improving the intestinal environment by promoting proliferation of intestinal lactic acid bacteria and the like. The present invention provides a food that is effective for improving the intestinal environment, wherein the food includes (1) ?-polyglutamic acid or a composition containing ?-polyglutamic acid, and (2) oligosaccharide or a composition containing oligosaccharide.

Abstract: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose, or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient.

Abstract: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose, or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient.

Abstract: The disclosure provides for immunomodulatory oligosaccharides, and uses thereof.

Abstract: One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. For example, the treatment and/or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as streptomycin and one or more of colistimethate, clindamycin, mupirocin, or levofloxacin.

Abstract: A method for treating a tumor or cancer by means of a treatment scheme of using endostatin in combination with induction of DNA double-strand breaks, and a medication. The method and composition are used for treating a tumor or cancer related to loss of p53 function, or a tumor or cancer occurring when p53 function is normal.

Abstract: The disclosure provides a CD169 high affinity anti-tumor compound (TCC-Neu5A) and its preparation and application. The CD169 high affinity anti-tumor compound is a small molecule compound, which has specific and broad-spectrum tumor killing characteristics. TCC-Neu5Ac could targets tumor cells in vivo and metabolize onto a surface of the tumor cells to form CD169 ligands. These tumor cells are recognized and phagocytized by CD169-positive macrophages, which then release tumor-related antigens and present them to other immune cells, triggering an anti-tumor immune response. The CD169 high affinity anti-tumor compound provided by the disclosure is effective for a variety of tumors and has an inhibitory effect on tumor metastasis. In addition, the CD169 high affinity anti-tumor compound provided by the disclosure can not only be injected but also be orally administered. Cytotoxicity and animal toxicity of the CD169 high affinity anti-tumor compound are very low.

Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody.

Abstract: The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.

Abstract: Described herein are methods and compositions related to the treatment or prevention of an inflammatory disease via administration of an agent that inhibits a long noncoding RNA (Inc-RNA) expressed in a macrophage to a subject in need thereof. In one embodiment, the Inc-RNA is lnc-FAM164A1. Another aspect herein provides a method of treating or preventing an inflammatory disease via administration of an agent that inhibits a protein bound to a Inc-RNA, e.g., ACLY, to a subject in need thereof.

Abstract: Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.

Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2Agene.

Abstract: Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-0, 3-O-desulfated heparin derivative.

Abstract: Described herein is the use of a methylated/sulfated hyaluronan, sulfated hyaluronan, or the pharmaceutically acceptable salt or ester thereof for the treatment of chronic rhinosinusitis.

Abstract: The present invention discloses a compound composition with function of promoting bone and joint health and an application thereof. In the present invention, glucosamine is combined with collagen, chondroitin sulfate and traditional Chinese medicine extract to prepare the compound composition with function of promoting bone and joint health. The compound composition can shorten onset time. At the same time, the traditional Chinese medicine extract for treating the bone and joint problems is added, to reduce the market impact of adding only modern joint health ingredients. Moreover, the compound composition disclosed by the present invention can be used as a dietary supplement or health food raw material for preventing or treating moderate to mild osteoarthritis. Thus, the compound composition disclosed by the present invention is suitable for promotion and application.

Abstract: The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.

Abstract: A hydrogen-supplying breathable layer in the present disclosure comprises: a thin layer wrapping a hydrogen-producing formula inside, having an airtight outer side as well as an air-permeable inner side on which a plurality of micro pores are opened and featuring a monolayer or a composite layer; a hydrogen-producing formula wrapped inside the thin layer and not dissipated but absorbing moistures in air or liquid water for generation of hydrogen; hydrogen permeating a plurality of micro pores and released to skin and intra-corporal parts. The hydrogen-producing formula in the hydrogen-supplying breathable layer comprises metal peroxides (metal hydroxides or metal hydrides) and aluminum powders (or silica powders); the breathable layer is applicable to a dressing pack or other sanitary paraphernalia in daily lives for relieving non-bacteria inflammations and promoting health care effects.

Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Abstract: The present invention provides a unique combination of herbal ingredients designed to improve human sexual performance and for the treatment of disorders of Male Sexual Dysfunction. The composition is comprised of Sulfur, Cnidium, Petrolatum Jelly, Cumin, Cassia, Schisandra, Eucommiacease, Borneal, Zingiber officinale in amounts effective to produce desired results.

Abstract: The invention is to provide a hydrogen sulfide sustained releasing dressing and a manufacturing method thereof. The hydrogen sulfide sustained releasing dressing includes a hydrocolloid, a surfactant and sodium hydro sulfide. The manufacturing method includes (a) heating and stirring a hydrocolloid material; (b) adding a surfactant and sodium hydrosulfide into the hydrocolloid material; and (c) injecting the hydrocolloid material containing the surfactant and the sodium hydrosulfide into a mold for thermoforming a hydrogen sulfide sustained releasing dressing.

Abstract: The present invention concerns a compound and composition for use in the preventive and/or curative treatment of diseases of the central nervous system characterised by a decline in neuronal plasticity, in particular a decline in synaptic plasticity, for example in the treatment of diseases of the central nervous system affecting cognitive processes such as learning, perception, attention, reasoning, language and/or memory, in the treatment of diseases of the central nervous system such as neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and/or amyotrophic lateral sclerosis, in the treatment of diseases of the central nervous system responsible for mood disorders, hyperexcitability, hyperactivity and/or stress, and in the treatment of neurological conditions such as epilepsy, said compound being magnesium N-acetyl taurinate

Abstract: In certain aspects, the present disclosure provides methods and materials for the treatment of cancer. In accordance with some forms, the disclosure provides methods for the treatment of cancer which include inhibition of ubiquitin carboxyl-terminal hydrolase.

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Abstract: A method of stimulating the synthesis of human and animal patient lung and sinus surfactants for treatment of lung damage needed to increase lung functions, increase oxygen levels, increase the synthesis of nasal nitric oxide and for inhibition of lung fibrosis while reducing, coughing, lung tightness, mouth breathing, and reducing congestion, for treating patients with a pulmonary condition including asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, sleep apnea and lung cancer, includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and, a salt of magnesium. Preferably, the composition is a saline solution.

Abstract: The present disclosure relates to topical compositions comprising water, solvent, thickener, preservative and conditioning agent wherein the composition has a viscosity approximately in the range 200-6000 cP at 25° C. following exposure to gamma radiation, to use of the composition in a dressing and the use of compositions and dressings in treatment or prophylaxis of burns.

Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for upregulating MHC class II in cancer cells (e.g., a hematological cancer cell). Also provided are methods of treatment for subjects suffering from hematological cancers, comprising administration of interferon-? (IFN-?). The methods of treatment provided herein may be particularly suitable for subjects who have received an allogenic transplant or have suffered a relapse.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

Abstract: The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: Compositions and methods for stimulating NK cell expansion and cytotoxicity are described. Therapeutic compositions and methods using expanded and stimulated NK cells are described.

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.

Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

Abstract: Multilineage-differentiating stress enduring (Muse) cells are stage-specific embryonic antigen-3 (SSEA-3) positive cells that exist in mesenchymal stem cell (MSC) populations. Muse cells have the pluripotency to differentiate into all germ layers as embryonic stem cells. The purpose of the present study is to investigate the efficacy of Muse cell transplantation for repairing osteochondral defects. Muse cells were isolated from human bone marrow MSCs. As osteochondral defects, the patellar grooves of immunodeficient rats were injured. Next, cells were injected into the mice so that the animals were divided into the following 3 groups: a control group to which PBS was injected; a non-Muse group to which 5×104 SSEA-3 negative non-Muse cells were injected; and a Muse group to which 5×104 SSEA-3 positive Muse cells were injected.

Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Streptococcus australis and their uses in treating metabolic-related diseases or disorder.

Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Gemella sanguinis and their uses in treating metabolic-related diseases or disorder.

Abstract: There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.